Yet, according to a cohort study, the use of SGLT2-targeted medicine in individuals diagnosed with type 2 diabetes was not found to be correlated with an increased incidence rate of venous thromboembolism (34). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.